|
|
|
T2 Biosystems Inc (NASDAQ: TTOO) |
|
T2 Biosystems Inc
Officers & Directors
JOHN M. SPRAGUE Company: BDO USA, P.C. JOHN SPERZEL Position: Not specified in the provided information. ,
T2 Biosystems Inc currently has 60 employees.
News about T2 Biosystems Inc Key Personnel |
T2 Biosystems Accelerates Development of New Diagnostic Products and Implements Stock Split Strategy to Benefit Shareholders
T2 Biosystems Inc. a pioneering company specializing in innovative diagnostic tools, has recently provided updates on its new product development pipeline progress. The company has announced plans to launch multiple direct-from-blood diagnostics within the next 15 months, focusing on addressing significant medical challenges such as antimicrobial resistance, pediatric Candida infections, Lyme disease, and Candida auris. These developments aim to revolutionize diagnostic methods and improve patient outcomes.
With an impressive scope of upcoming products, T2 Biosystems is demonst...
|
In a major step towards expanding its commercial presence, T2 Biosystems, Inc. (NASDAQ:TTOO), a pioneer in rapidly detecting sepsis-causing pathogens and antibiotic resistant genes, has announced the signing of an exclusive distribution agreement for Hong Kong and Macau. This strategic move aims to strengthen the company s foothold in the Asian market and provide advanced diagnostic tools in the battle against sepsis.
Under the terms of the agreement, T2 Biosystems will now offer its state-of-the-art T2Dx Instrument, T2Bacteria Panel, T2Candida Panel, and T2Resistance Panel through its newly appointed distributor in Hong Kong and Macau. This breakthrough technology enables healthcare professio...
|
T2 Biosystems: Strategies for Growth and Economic Resilience
In recent developments, T2 Biosystems Inc, a prominent developer of innovative diagnostic tools, has announced two significant moves with varying implications for the company. Firstly, T2 Biosystems revealed its intention to forge a strategic partnership for Lyme disease and, concurrently, unveiled plans to launch the T2Lyme Panel for the early detection of Lyme disease. Additionally, the company declared that its common stock would commence trading on a split-adjusted basis in order to benefit its shareholders.
The decision to develop a strategic partnership for Lyme disease and introduce the T2Lyme Panel demonstrates T2 Biosystems commit...
|
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
